Literature DB >> 9603433

Molecular basis of type III hyperlipoproteinemia in Germany.

G Feussner1, V Feussner, M M Hoffmann, J Lohrmann, H Wieland, W März.   

Abstract

Type III hyperlipoproteinemia (HLP) is usually associated with homozygosity for apolipoprotein (apo) E2 (Arg112 --> Cys, Arg158 --> Cys). This common apo E isoform is defective in its binding to lipoprotein receptors. However, other rare mutations in the apo epsilon gene may also, in part dominantly, predispose to the disease. In order to assess the prevalence of rare apo E variants and mutations in the apo epsilon gene in Germany, we examined apo epsilon genotypes by restriction isotyping (RI) and apo E phenotypes by isoelectric focusing (IEF) in 107 German patients with type III HLP. Concordance between apo epsilon genotype and apo E phenotype was observed in 101 subjects (94.4%). Six individuals (5.6%) had genotypes and phenotypes other than E2/2. One subject was apparently homozygous for apo E2 by IEF, but heterozygous for epsilon3/2 by RI. Sequencing of the apo epsilon gene disclosed a hitherto undescribed point mutation (TGG --> TGA) at the third position of the codon for amino acid 20 (Trp), introducing a premature termination codon. This is the first study demonstrating that in the German population type III HLP is mainly associated with homozygosity for apo E2 (Arg112 --> Cys, Arg158 --> Cys) and that discrepancies between apo epsilon genotype and apo E phenotype are rare in this genetic condition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603433     DOI: 10.1002/(SICI)1098-1004(1998)11:6<417::AID-HUMU1>3.0.CO;2-5

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

1.  Impairment of gastric nitrergic and NRF2 system in apolipoprotein E knockout mice.

Authors:  Kalpana Ravella; Hong Yang; Pandu R R Gangula
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

2.  DDDAS Design of Drug Interventions for the Treatment of Dyslipidemia in ApoE-/- Mice.

Authors:  Brittney Metts; Sean Thatcher; Eboni Lewis; Mike Karounos; Lisa Cassis; Rebecca Smith; Robert A Lodder
Journal:  J Dev Drugs       Date:  2013-10

Review 3.  [Congenital disorders of lipoprotein metabolism].

Authors:  W März; T B Grammer; G Delgado; M E Kleber
Journal:  Herz       Date:  2017-08       Impact factor: 1.443

4.  Apolipoprotein E (Apo E) gene polymorphisms and recurrent pregnancy loss: a meta-analysis.

Authors:  Jie Li; Yang Chen; Hongbo Wu; Liuming Li
Journal:  J Assist Reprod Genet       Date:  2013-11-13       Impact factor: 3.412

5.  Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology.

Authors:  Nader Ghebranious; Lynn Ivacic; Jamie Mallum; Charles Dokken
Journal:  Nucleic Acids Res       Date:  2005-10-04       Impact factor: 16.971

Review 6.  Large animal models of cardiovascular disease.

Authors:  H G Tsang; N A Rashdan; C B A Whitelaw; B M Corcoran; K M Summers; V E MacRae
Journal:  Cell Biochem Funct       Date:  2016-02-24       Impact factor: 3.685

7.  A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism.

Authors:  Li Zhong; Yong-Zhuang Xie; Tian-Tian Cao; Zongqi Wang; Tingting Wang; Xinxiu Li; Rui-Chi Shen; Huaxi Xu; Guojun Bu; Xiao-Fen Chen
Journal:  Mol Neurodegener       Date:  2016-01-12       Impact factor: 14.195

8.  Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene.

Authors:  Trond P Leren; Thea Bismo Strøm; Knut Erik Berge
Journal:  Mol Genet Metab Rep       Date:  2016-10-25

9.  The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.

Authors:  Manish D Paranjpe; Xueqi Chen; Min Liu; Ishan Paranjpe; Jeffrey P Leal; Rongfu Wang; Martin G Pomper; Dean F Wong; Tammie L S Benzinger; Yun Zhou
Journal:  Neuroimage Clin       Date:  2019-03-28       Impact factor: 4.881

Review 10.  Role of apolipoprotein E in neurodegenerative diseases.

Authors:  Vo Van Giau; Eva Bagyinszky; Seong Soo A An; Sang Yun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.